Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection

Purpose To test the efficacy, duration and safety of 100 U of botulinum toxin type A (BoNT/A) in women affected by idiopathic detrusor overactivity (IDO) and the effectiveness of subsequent injections. Methods In this double centre, prospective study conducted from March 2008 to March 2010, we selec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of gynecology and obstetrics 2012-10, Vol.286 (4), p.923-929
Hauptverfasser: Granese, Roberta, Adile, Giorgio, Gugliotta, Giorgio, Cucinella, Gaspare, Saitta, Salvatore, Adile, Biagio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 929
container_issue 4
container_start_page 923
container_title Archives of gynecology and obstetrics
container_volume 286
creator Granese, Roberta
Adile, Giorgio
Gugliotta, Giorgio
Cucinella, Gaspare
Saitta, Salvatore
Adile, Biagio
description Purpose To test the efficacy, duration and safety of 100 U of botulinum toxin type A (BoNT/A) in women affected by idiopathic detrusor overactivity (IDO) and the effectiveness of subsequent injections. Methods In this double centre, prospective study conducted from March 2008 to March 2010, we selected women affected by IDO who failed to respond to various antimuscarinic agents, reported intolerable anticholinergic side-effects or contraindication to their use, also without any response to tibial stimulation. Medical history, physical examination, standard urodynamic examination, urinalysis, urine culture, a 4-day voiding diary and a quality of life questionnaire were requested for all patients. A total amount of 100 U of BoNT/A were injected into the detrusor muscle. A second injection of BoNT/A was suggested to patients who experienced a relapse of initially improved symptoms. Results We enrolled a total number of 68 women. All patients showed significant improvement in urodynamic parameters, clinical features and quality of life, after the first injection of Botox ® until the 9 months of follow-up. Even after the second injection, with a follow-up of 3 months, we obtained results comparable with the first injection. Side-effects include an increase in post-void residual volume, dysuria and urinary infections. Conclusions We considered the dose of 100 U of Botox ® , for treatment of IDO, as an efficacious and safe solution compared to other therapeutic options, without serious and lasting adverse effects for women, even after a second injection.
doi_str_mv 10.1007/s00404-012-2349-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1039344568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1039344568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-1e06da9c41a84b8b71f3fa7ecee1f86c3aab03bb42c1518fe33fdda0eedaa4f93</originalsourceid><addsrcrecordid>eNp1kU1uFDEQRq0oUTIEDpANspRNFnTw33S72UEUIFIkNrC2qu1y8GjGHuzuiLkUh8jJcDNJkJBYuaR69Vz6ipAzzi45Y93bwphiqmFcNEKqvtEHZMGVFA3rOD8kC9bPNWu7E_KilBWroNbtMTkRohVCq35B0oc0pp8Pv6hPmQYX0hbG78HSdI8Z7BjukQ5rcA7zO4reBwt294a6KcMYUqQQHS3gcdxd0mvv8c9ExFJo8rRMQ8EfE8aRhriaeym-JEce1gVfPb6n5NvH669Xn5vbL59urt7fNlYpMTYcWeugt4qDVoMeOu6lhw4tIve6tRJgYHIYlLB8ybVHKb1zwBAdgPK9PCUXe-82p7pCGc0mFIvrNURMUzGcyV4qtWx1Rc__QVdpyrFuZ2pOfKk6uZyFfE_ZnErJ6M02hw3kXVWZ-Rpmfw1TQzbzNcxsfv1onoYNuueJp_grIPZAqa14h_nv1_-3_gZ_l5fu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2261547359</pqid></control><display><type>article</type><title>Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Granese, Roberta ; Adile, Giorgio ; Gugliotta, Giorgio ; Cucinella, Gaspare ; Saitta, Salvatore ; Adile, Biagio</creator><creatorcontrib>Granese, Roberta ; Adile, Giorgio ; Gugliotta, Giorgio ; Cucinella, Gaspare ; Saitta, Salvatore ; Adile, Biagio</creatorcontrib><description>Purpose To test the efficacy, duration and safety of 100 U of botulinum toxin type A (BoNT/A) in women affected by idiopathic detrusor overactivity (IDO) and the effectiveness of subsequent injections. Methods In this double centre, prospective study conducted from March 2008 to March 2010, we selected women affected by IDO who failed to respond to various antimuscarinic agents, reported intolerable anticholinergic side-effects or contraindication to their use, also without any response to tibial stimulation. Medical history, physical examination, standard urodynamic examination, urinalysis, urine culture, a 4-day voiding diary and a quality of life questionnaire were requested for all patients. A total amount of 100 U of BoNT/A were injected into the detrusor muscle. A second injection of BoNT/A was suggested to patients who experienced a relapse of initially improved symptoms. Results We enrolled a total number of 68 women. All patients showed significant improvement in urodynamic parameters, clinical features and quality of life, after the first injection of Botox ® until the 9 months of follow-up. Even after the second injection, with a follow-up of 3 months, we obtained results comparable with the first injection. Side-effects include an increase in post-void residual volume, dysuria and urinary infections. Conclusions We considered the dose of 100 U of Botox ® , for treatment of IDO, as an efficacious and safe solution compared to other therapeutic options, without serious and lasting adverse effects for women, even after a second injection.</description><identifier>ISSN: 0932-0067</identifier><identifier>EISSN: 1432-0711</identifier><identifier>DOI: 10.1007/s00404-012-2349-8</identifier><identifier>PMID: 22622849</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Aged ; Botulinum toxin ; Botulinum Toxins, Type A - administration &amp; dosage ; Botulinum Toxins, Type A - adverse effects ; Cystoscopy ; Endocrinology ; Female ; General Gynecology ; Gynecology ; Human Genetics ; Humans ; Injections, Intramuscular ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Obstetrics/Perinatology/Midwifery ; Prospective Studies ; Quality of life ; Reoperation ; Treatment Outcome ; Urinary Bladder, Overactive - drug therapy ; Urinary Bladder, Overactive - surgery ; Urinary tract infections</subject><ispartof>Archives of gynecology and obstetrics, 2012-10, Vol.286 (4), p.923-929</ispartof><rights>Springer-Verlag 2012</rights><rights>Archives of Gynecology and Obstetrics is a copyright of Springer, (2012). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-1e06da9c41a84b8b71f3fa7ecee1f86c3aab03bb42c1518fe33fdda0eedaa4f93</citedby><cites>FETCH-LOGICAL-c442t-1e06da9c41a84b8b71f3fa7ecee1f86c3aab03bb42c1518fe33fdda0eedaa4f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00404-012-2349-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00404-012-2349-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22622849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Granese, Roberta</creatorcontrib><creatorcontrib>Adile, Giorgio</creatorcontrib><creatorcontrib>Gugliotta, Giorgio</creatorcontrib><creatorcontrib>Cucinella, Gaspare</creatorcontrib><creatorcontrib>Saitta, Salvatore</creatorcontrib><creatorcontrib>Adile, Biagio</creatorcontrib><title>Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection</title><title>Archives of gynecology and obstetrics</title><addtitle>Arch Gynecol Obstet</addtitle><addtitle>Arch Gynecol Obstet</addtitle><description>Purpose To test the efficacy, duration and safety of 100 U of botulinum toxin type A (BoNT/A) in women affected by idiopathic detrusor overactivity (IDO) and the effectiveness of subsequent injections. Methods In this double centre, prospective study conducted from March 2008 to March 2010, we selected women affected by IDO who failed to respond to various antimuscarinic agents, reported intolerable anticholinergic side-effects or contraindication to their use, also without any response to tibial stimulation. Medical history, physical examination, standard urodynamic examination, urinalysis, urine culture, a 4-day voiding diary and a quality of life questionnaire were requested for all patients. A total amount of 100 U of BoNT/A were injected into the detrusor muscle. A second injection of BoNT/A was suggested to patients who experienced a relapse of initially improved symptoms. Results We enrolled a total number of 68 women. All patients showed significant improvement in urodynamic parameters, clinical features and quality of life, after the first injection of Botox ® until the 9 months of follow-up. Even after the second injection, with a follow-up of 3 months, we obtained results comparable with the first injection. Side-effects include an increase in post-void residual volume, dysuria and urinary infections. Conclusions We considered the dose of 100 U of Botox ® , for treatment of IDO, as an efficacious and safe solution compared to other therapeutic options, without serious and lasting adverse effects for women, even after a second injection.</description><subject>Adult</subject><subject>Aged</subject><subject>Botulinum toxin</subject><subject>Botulinum Toxins, Type A - administration &amp; dosage</subject><subject>Botulinum Toxins, Type A - adverse effects</subject><subject>Cystoscopy</subject><subject>Endocrinology</subject><subject>Female</subject><subject>General Gynecology</subject><subject>Gynecology</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Obstetrics/Perinatology/Midwifery</subject><subject>Prospective Studies</subject><subject>Quality of life</subject><subject>Reoperation</subject><subject>Treatment Outcome</subject><subject>Urinary Bladder, Overactive - drug therapy</subject><subject>Urinary Bladder, Overactive - surgery</subject><subject>Urinary tract infections</subject><issn>0932-0067</issn><issn>1432-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU1uFDEQRq0oUTIEDpANspRNFnTw33S72UEUIFIkNrC2qu1y8GjGHuzuiLkUh8jJcDNJkJBYuaR69Vz6ipAzzi45Y93bwphiqmFcNEKqvtEHZMGVFA3rOD8kC9bPNWu7E_KilBWroNbtMTkRohVCq35B0oc0pp8Pv6hPmQYX0hbG78HSdI8Z7BjukQ5rcA7zO4reBwt294a6KcMYUqQQHS3gcdxd0mvv8c9ExFJo8rRMQ8EfE8aRhriaeym-JEce1gVfPb6n5NvH669Xn5vbL59urt7fNlYpMTYcWeugt4qDVoMeOu6lhw4tIve6tRJgYHIYlLB8ybVHKb1zwBAdgPK9PCUXe-82p7pCGc0mFIvrNURMUzGcyV4qtWx1Rc__QVdpyrFuZ2pOfKk6uZyFfE_ZnErJ6M02hw3kXVWZ-Rpmfw1TQzbzNcxsfv1onoYNuueJp_grIPZAqa14h_nv1_-3_gZ_l5fu</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Granese, Roberta</creator><creator>Adile, Giorgio</creator><creator>Gugliotta, Giorgio</creator><creator>Cucinella, Gaspare</creator><creator>Saitta, Salvatore</creator><creator>Adile, Biagio</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20121001</creationdate><title>Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection</title><author>Granese, Roberta ; Adile, Giorgio ; Gugliotta, Giorgio ; Cucinella, Gaspare ; Saitta, Salvatore ; Adile, Biagio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-1e06da9c41a84b8b71f3fa7ecee1f86c3aab03bb42c1518fe33fdda0eedaa4f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Botulinum toxin</topic><topic>Botulinum Toxins, Type A - administration &amp; dosage</topic><topic>Botulinum Toxins, Type A - adverse effects</topic><topic>Cystoscopy</topic><topic>Endocrinology</topic><topic>Female</topic><topic>General Gynecology</topic><topic>Gynecology</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Obstetrics/Perinatology/Midwifery</topic><topic>Prospective Studies</topic><topic>Quality of life</topic><topic>Reoperation</topic><topic>Treatment Outcome</topic><topic>Urinary Bladder, Overactive - drug therapy</topic><topic>Urinary Bladder, Overactive - surgery</topic><topic>Urinary tract infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Granese, Roberta</creatorcontrib><creatorcontrib>Adile, Giorgio</creatorcontrib><creatorcontrib>Gugliotta, Giorgio</creatorcontrib><creatorcontrib>Cucinella, Gaspare</creatorcontrib><creatorcontrib>Saitta, Salvatore</creatorcontrib><creatorcontrib>Adile, Biagio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Granese, Roberta</au><au>Adile, Giorgio</au><au>Gugliotta, Giorgio</au><au>Cucinella, Gaspare</au><au>Saitta, Salvatore</au><au>Adile, Biagio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection</atitle><jtitle>Archives of gynecology and obstetrics</jtitle><stitle>Arch Gynecol Obstet</stitle><addtitle>Arch Gynecol Obstet</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>286</volume><issue>4</issue><spage>923</spage><epage>929</epage><pages>923-929</pages><issn>0932-0067</issn><eissn>1432-0711</eissn><abstract>Purpose To test the efficacy, duration and safety of 100 U of botulinum toxin type A (BoNT/A) in women affected by idiopathic detrusor overactivity (IDO) and the effectiveness of subsequent injections. Methods In this double centre, prospective study conducted from March 2008 to March 2010, we selected women affected by IDO who failed to respond to various antimuscarinic agents, reported intolerable anticholinergic side-effects or contraindication to their use, also without any response to tibial stimulation. Medical history, physical examination, standard urodynamic examination, urinalysis, urine culture, a 4-day voiding diary and a quality of life questionnaire were requested for all patients. A total amount of 100 U of BoNT/A were injected into the detrusor muscle. A second injection of BoNT/A was suggested to patients who experienced a relapse of initially improved symptoms. Results We enrolled a total number of 68 women. All patients showed significant improvement in urodynamic parameters, clinical features and quality of life, after the first injection of Botox ® until the 9 months of follow-up. Even after the second injection, with a follow-up of 3 months, we obtained results comparable with the first injection. Side-effects include an increase in post-void residual volume, dysuria and urinary infections. Conclusions We considered the dose of 100 U of Botox ® , for treatment of IDO, as an efficacious and safe solution compared to other therapeutic options, without serious and lasting adverse effects for women, even after a second injection.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22622849</pmid><doi>10.1007/s00404-012-2349-8</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0932-0067
ispartof Archives of gynecology and obstetrics, 2012-10, Vol.286 (4), p.923-929
issn 0932-0067
1432-0711
language eng
recordid cdi_proquest_miscellaneous_1039344568
source MEDLINE; SpringerLink Journals
subjects Adult
Aged
Botulinum toxin
Botulinum Toxins, Type A - administration & dosage
Botulinum Toxins, Type A - adverse effects
Cystoscopy
Endocrinology
Female
General Gynecology
Gynecology
Human Genetics
Humans
Injections, Intramuscular
Medicine
Medicine & Public Health
Middle Aged
Obstetrics/Perinatology/Midwifery
Prospective Studies
Quality of life
Reoperation
Treatment Outcome
Urinary Bladder, Overactive - drug therapy
Urinary Bladder, Overactive - surgery
Urinary tract infections
title Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T07%3A43%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Botox%C2%AE%20for%20idiopathic%20overactive%20bladder:%20efficacy,%20duration%20and%20safety.%20Effectiveness%20of%20subsequent%20injection&rft.jtitle=Archives%20of%20gynecology%20and%20obstetrics&rft.au=Granese,%20Roberta&rft.date=2012-10-01&rft.volume=286&rft.issue=4&rft.spage=923&rft.epage=929&rft.pages=923-929&rft.issn=0932-0067&rft.eissn=1432-0711&rft_id=info:doi/10.1007/s00404-012-2349-8&rft_dat=%3Cproquest_cross%3E1039344568%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2261547359&rft_id=info:pmid/22622849&rfr_iscdi=true